BACKGROUND: Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. AIM: We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. METHODS: Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. RESULTS: After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86% in mice without chemotherapy, p<0.05) and decrease in alkaline phosphatase levels (42.78 ± 6.06 vs 60.62 ± 6.23 IU/l in mice without chemotherapy, p<0.05), consistent with osteoporosis from impaired bone formation. Administration of a single dose of PTH-CBD (320 μg/kg ip) prior to CYP treatment improved BMD (change from baseline: 23.4 ± 5.4 vs 7.4 ± 6.9%, CYP treatment alone, p<0.05) and increased alkaline phosphatase levels (50.14 ± 4.86 vs 42.78 ± 6.06 IU/l in CYP treatment alone, p<0.05). BMD values and alkaline phosphatase levels were restored to those seen in mice not receiving chemotherapy. CONCLUSIONS: A single dose of PTHCBD prior to chemotherapy reversed CYP-induced suppression of bone formation and prevented CYP-induced bone loss in mice.
BACKGROUND: Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. AIM: We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. METHODS:Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. RESULTS: After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86% in mice without chemotherapy, p<0.05) and decrease in alkaline phosphatase levels (42.78 ± 6.06 vs 60.62 ± 6.23 IU/l in mice without chemotherapy, p<0.05), consistent with osteoporosis from impaired bone formation. Administration of a single dose of PTH-CBD (320 μg/kg ip) prior to CYP treatment improved BMD (change from baseline: 23.4 ± 5.4 vs 7.4 ± 6.9%, CYP treatment alone, p<0.05) and increased alkaline phosphatase levels (50.14 ± 4.86 vs 42.78 ± 6.06 IU/l in CYP treatment alone, p<0.05). BMD values and alkaline phosphatase levels were restored to those seen in mice not receiving chemotherapy. CONCLUSIONS: A single dose of PTHCBD prior to chemotherapy reversed CYP-induced suppression of bone formation and prevented CYP-induced bone loss in mice.
Authors: Tulasi Ponnapakkam; R Katikaneni; E Miller; A Ponnapakkam; S Hirofumi; S Miyata; L J Suva; J Sakon; O Matsushita; R C Gensure Journal: Calcif Tissue Int Date: 2011-04-22 Impact factor: 4.333
Authors: T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto Journal: Cell Date: 1997-05-30 Impact factor: 41.582
Authors: Z Chen; M Maricic; A K Aragaki; C Mouton; L Arendell; A M Lopez; T Bassford; R T Chlebowski Journal: Osteoporos Int Date: 2008-09-03 Impact factor: 4.507
Authors: Angela Wittelsberger; Martina Corich; Beena E Thomas; Byung-Kwon Lee; Alessandra Barazza; Paul Czodrowski; Dale F Mierke; Michael Chorev; Michael Rosenblatt Journal: Biochemistry Date: 2006-02-21 Impact factor: 3.162
Authors: Cynthia R Sides; Rohana Liyanage; Jackson O Lay; Sagaya Theresa Leena Philominathan; Osamu Matsushita; Joshua Sakon Journal: J Am Soc Mass Spectrom Date: 2011-12-30 Impact factor: 3.109
Authors: Chiaming Fan; Kristen R Georgiou; Ross A McKinnon; Dorothy M K Keefe; Peter R C Howe; Cory J Xian Journal: J Bone Miner Metab Date: 2015-06-09 Impact factor: 2.626
Authors: Li-Wen Huang; Dong Sun; Thomas M Link; Thomas Lang; Weiyun Ai; Lawrence D Kaplan; Michael A Steinman; Charalambos Andreadis Journal: Support Care Cancer Date: 2021-03-10 Impact factor: 3.603